Kim B, Warnaka P, Iverson M, Imbembo A L
Department of Surgery, Cleveland Metropolitan General Hospital, OH 44109.
Arch Surg. 1987 Dec;122(12):1455-9. doi: 10.1001/archsurg.1987.01400240103019.
Tumor-induced immune suppression of the host may pose a barrier to successful immunotherapy. A monoclonal antibody (MAb 14-12) able to bind and inhibit murine soluble T-cell suppressor factor was tested for in vivo antitumor activity by treatment of mice bearing three-day established pulmonary metastases of a weakly immunogenic methylcholanthrene-induced fibrosarcoma (MCA 106). Administration intraperitoneally in combination with interleukin 2 (IL-2), a growth factor for activated T lymphocytes, resulted in a significant reduction (60% to 90%) of metastases. Neither IL-2 nor monoclonal antibody alone had significant antitumor effects. This study demonstrates in vivo potentiation of IL-2 antitumor activity with an anti-T-cell suppressor factor and points to possible strategies for clinical application.
肿瘤诱导的宿主免疫抑制可能对成功的免疫治疗构成障碍。一种能够结合并抑制小鼠可溶性T细胞抑制因子的单克隆抗体（MAb 14-12），通过对携带由弱免疫原性的甲基胆蒽诱导的纤维肉瘤（MCA 106）形成三天的肺转移瘤的小鼠进行治疗，来测试其体内抗肿瘤活性。与白细胞介素2（IL-2，一种活化T淋巴细胞的生长因子）联合腹腔注射，导致转移瘤显著减少（60%至90%）。单独使用IL-2或单克隆抗体均无显著抗肿瘤作用。本研究证明了抗T细胞抑制因子对IL-2抗肿瘤活性的体内增强作用，并指出了可能的临床应用策略。
